Hasil Pencarian - Lars Wallentin

Perbaiki Hasil
  1. 1
    Uppsala Clinical Research Center—development of a platform to promote national and international clinical science

    Uppsala Clinical Research Center—development of a platform to promote national and international clinical science oleh Lars Wallentin, Bertil Lindahl

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome.

    Genome-Wide Association Study Identifies That the ABO Blood Group System Influences Interleukin-10 Levels and the Risk of Clinical Events in Patients with Acute Coronary Syndrome. oleh Åsa Johansson, Jenny Alfredsson, Niclas Eriksson, Lars Wallentin, Agneta Siegbahn

    Diterbitkan 2015-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

    Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events oleh Sofia Attelind, Pär Hallberg, Mia Wadelius, Anna-Karin Hamberg, Agneta Siegbahn, Agneta Siegbahn, Christopher B. Granger, Renato D. Lopes, John H. Alexander, Lars Wallentin, Lars Wallentin, Niclas Eriksson

    Diterbitkan 2022-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Serum Neurofilament Light Chain in Patients With Atrial Fibrillation

    Serum Neurofilament Light Chain in Patients With Atrial Fibrillation oleh Karl Sjölin, Julia Aulin, Lars Wallentin, Niclas Eriksson, Claes Held, Kim Kultima, Jonas Oldgren, Joachim Burman

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men.

    GDF-15 for prognostication of cardiovascular and cancer morbidity and mortality in men. oleh Lars Wallentin, Björn Zethelius, Lars Berglund, Kai M Eggers, Lars Lind, Bertil Lindahl, Kai C Wollert, Agneta Siegbahn

    Diterbitkan 2013-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome?

    Antibodies against MYC-Associated Zinc Finger Protein: An Independent Marker in Acute Coronary Syndrome? oleh Diana Ernst, Christian Widera, Niklas T. Baerlecken, Wolfgang Schlumberger, Cornelia Daehnrich, Reinhold E. Schmidt, Katja Gabrysch, Lars Wallentin, Torsten Witte

    Diterbitkan 2017-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy

    Body Mass Index and Association With Cardiovascular Outcomes in Patients With Stable Coronary Heart Disease – A STABILITY Substudy oleh Claes Held, Nermin Hadziosmanovic, Philip E. Aylward, Emil Hagström, Judith S. Hochman, Ralph A. H. Stewart, Harvey D. White, Lars Wallentin

    Diterbitkan 2022-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis

    Factor V Leiden Does Not Modify the Phenotype of Acute Coronary Syndrome or the Extent of Myocardial Necrosis oleh Bakhtawar K. Mahmoodi, Niclas Eriksson, Gerrit J. A. Vos, Karina Meijer, Agneta Siegbahn, Stefan James, Lars Wallentin, Jurriën M. ten Berg

    Diterbitkan 2021-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21).

    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21). oleh Agneta Siegbahn, Niclas Eriksson, Erika Assarsson, Martin Lundberg, Andrea Ballagi, Claes Held, Ralph A H Stewart, Harvey D White, Mikael Åberg, Lars Wallentin

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21)

    Development and validation of a quantitative Proximity Extension Assay instrument with 21 proteins associated with cardiovascular risk (CVD-21) oleh Agneta Siegbahn, Niclas Eriksson, Erika Assarsson, Martin Lundberg, Andrea Ballagi, Claes Held, Ralph A. H. Stewart, Harvey D. White, Mikael Åberg, Lars Wallentin

    Diterbitkan 2023-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease

    Cardiovascular and Lifestyle Risk Factors and Cognitive Function in Patients With Stable Coronary Heart Disease oleh Ralph A. H. Stewart, Claes Held, Sue Krug‐Gourley, Dawn Waterworth, Amanda Stebbins, Karen Chiswell, Emil Hagstrom, Paul W. Armstrong, Lars Wallentin, Harvey White

    Diterbitkan 2019-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Angina, "normal" coronary angiography, and vascular dysfunction: risk assessment strategies.

    Angina, "normal" coronary angiography, and vascular dysfunction: risk assessment strategies. oleh Raffaele Bugiardini, Lina Badimon, Peter Collins, Raimund Erbel, Kim Fox, Christian Hamm, Fausto Pinto, Annika Rosengren, Christodoulos Stefanadis, Lars Wallentin, Frans Van de Werf

    Diterbitkan 2007-02-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study.

    Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. oleh Finlay A McAlister, Rajibul Mian, Jonas Oldgren, Lars Wallentin, Michael Ezekowitz, Salim Yusuf, Stuart J Connolly, Jeff S Healey, RE-LY Atrial Fibrillation Registry Investigators

    Diterbitkan 2020-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights From the ARISTOTLE Trial

    Repeated Measurement of the Novel Atrial Biomarker BMP10 (Bone Morphogenetic Protein 10) Refines Risk Stratification in Anticoagulated Patients With Atrial Fibrillation: Insights F... oleh Konstantinos I. Gkarmiris, Johan Lindbäck, John H. Alexander, Christopher B. Granger, Peter Kastner, Renato D. Lopes, André Ziegler, Jonas Oldgren, Agneta Siegbahn, Lars Wallentin, Ziad Hijazi

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy

    Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudy oleh Thomas A. Nelson, William A.E. Parker, Tatevik Ghukasyan Lakic, Johan Westerbergh, Stefan K. James, Agneta Siegbahn, Richard C. Becker, Anders Himmelmann, Lars Wallentin, Robert F. Storey

    Diterbitkan 2022-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials

    Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials oleh Bakhtawar K. Mahmoodi, Niclas Eriksson, Stephanie Ross, Daniel M. F. Claassens, Folkert W. Asselbergs, Karina Meijer, Agneta Siegbahn, Stefan James, Guillaume Pare, Lars Wallentin, Jurriën M. ten Berg

    Diterbitkan 2021-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial

    Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial oleh Peter T. Hu, Renato D. Lopes, Susanna R. Stevens, Lars Wallentin, Laine Thomas, John H. Alexander, Michael Hanna, Basil S. Lewis, Freek W. A. Verheugt, Christopher B. Granger, W. Schuyler Jones

    Diterbitkan 2017-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and Patient Outcomes) Trial

    Osteoprotegerin Is Associated With Major Bleeding But Not With Cardiovascular Outcomes in Patients With Acute Coronary Syndromes: Insights From the PLATO (Platelet Inhibition and P... oleh Thor Ueland, Axel Åkerblom, Tatevik Ghukasyan, Annika E. Michelsen, Pål Aukrust, Richard C. Becker, Maria Bertilsson, Anders Himmelmann, Stefan K. James, Agneta Siegbahn, Robert F. Storey, Frederic Kontny, Lars Wallentin

    Diterbitkan 2018-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial

    Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE‐LY Trial oleh Ziad Hijazi, Paolo Verdecchia, Jonas Oldgren, Ulrika Andersson, Gianpaolo Reboldi, Giuseppe Di Pasquale, Giovanni Mazzotta, Fabio Angeli, John W. Eikelboom, Michael D. Ezekowitz, Stuart J. Connolly, Salim Yusuf, Lars Wallentin

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy

    Prediction of Residual Risk by Ceramide‐Phospholipid Score in Patients With Stable Coronary Heart Disease on Optimal Medical Therapy oleh Mika Hilvo, Lars Wallentin, Tatevik Ghukasyan Lakic, Claes Held, Dimple Kauhanen, Antti Jylhä, Johan Lindbäck, Agneta Siegbahn, Christopher B. Granger, Wolfgang Koenig, Ralph A. H. Stewart, Harvey White, Reijo Laaksonen

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: